NRx Pharmaceuticals, Inc. (NRXP) Tops Q3 EPS by 4c

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) reported Q3 EPS of ($0.07), $0.04 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on NRx Pharmaceuticals, Inc. (NRXP) click here.

You May Also Be Interested In

• Norwegian Cruise Line Holdings (NYSE: NCLH) PT Raised to $20 at UBS
• Home Depot (HD) Tops Q2 EPS by 19c, reaffirms guidance
• Enhanced Group plans AI health platform launch in 2026